Benchling for RNA Therapeutics R&D
Oct 20, 2021
Because RNA therapeutics can target conditions that small molecules and proteins cannot address, researchers are now on the verge of treating previously “undruggable” diseases. From the approval of the first antisense oligonucleotide, aptamer, and siRNA, to the now famous launch of mRNA-based COVID-19 vaccines, the pipeline of RNA therapies and vaccines has expanded dramatically. However, as RNA therapeutics have gained traction scientifically and clinically, the software tools to engineer them have been frustratingly limited. This application note discusses complexities in RNA therapeutics R&D as well as how Benchling can help overcome these hurdles.
Benchling for RNA Therapeutics R&D.pdf
- Radiolabelling Nucleic Acids with [γ-32P] ATP for Analytical Assays
- Generating and maintaining uniform 3D spheroids in long term cultures
- Noninvasive 3D imaging Using Optical Coherence Tomography
- Streamlined High Throughput Drug Screening with PrimeSurface® White 384 well 3D plates